Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -202,11 +202,11 @@
202	202
203	203	The company may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct its business, and may be subject to claims that the company infringe or otherwise violate the intellectual property rights of others, which could materially harm its business. For a more comprehensive summary of the risks related to its intellectual property, see “Risk Factors.”
204	204
205		-==== Sales and Marketing ====
	205	+= Sales and Marketing =
206	206
207	207	Vascular Biogenics has not yet established sales, marketing or product distribution operations because its lead candidates are still in early clinical development.
208	208
209		-==== Manufacturing ====
	209	+= Manufacturing =
210	210
211	211	The company generally perform process development for its drug substance candidates and manufacture quantities of its drug candidates necessary to conduct pre-clinical studies and clinical trials of its drug candidates. The company rely on third-party manufacturers to produce bulk drug substance required for its clinical trials and expect to continue to rely on third parties to manufacture clinical trial drug supplies for the foreseeable future. The company also contract with additional third parties for the formulating, labeling, packaging, storage and distribution of the final drug products.
212	212
...	...	@@ -216,7 +216,7 @@
216	216
217	217	In October 2017, the company announced the opening of its new gene therapy manufacturing plant in Modiin, Israel. This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec (VB-111), if approved. The site design enables modular expansion of the manufacturing capacity, to supply growing demand following commercialization. The Modiin facility shall also enable it to comply with the restrictions of the Research Law and its undertaking to the OCS that an essential portion of its VB-111 production, and in any event not less than the majority of VB-111 production, will remain in Israel. The investment in the facility is included in the Company’s budget and was also supported by the Israel Innovation Authority. VBL expects that its current cash will fund the Company’s operating expenses and capital expenditure requirements through 2020.
218	218
219		-==== Employees ====
	219	+= Employees =
220	220
221	221	As of March 1, 2018, the company employed 37 employees, including 30 in research and development, and 7 in general and administrative positions, and of which 14 employees have either MDs or PhDs. All of its employees are located in Israel. The company believe its employee relations are good.
222	222
...	...	@@ -224,6 +224,8 @@
224	224
225	225	None of its employees currently work under any collective bargaining agreements.
226	226
227		-==== Property ====
	227	+= Property =
228	228
229	229	The company's corporate headquarters and research facilities are currently located in Modi’in, Israel, where the company lease an aggregate of approximately 21,500 square feet of office and laboratory space, pursuant to a lease agreement that expires in June 2023. This facility additionally houses its clinical development, clinical operations, regulatory and management functions, as well as its local biological drugs manufacturing facility.
	230	+
	231	+= References =